Effectiveness of dapagliflozin in nonalcoholic fatty liver disease in type 2 diabetes patients compared to sitagliptin and pioglitazone

被引：0
|
作者：
Koutsovasilis, A.
Sotiropoulos, A.
Bletsa, E.
Antoniou, A.
Tamvakos, C.
Ntionias, D.
Bousboulas, S.
Peppas, T.
机构：
[1] Gen Hosp Nikaia Piraeus, Dept Internal Med 3, Athens, Greece
[2] Gen Hosp Nikaia Piraeus, Ctr Diabet, Athens, Greece
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
12
引用
收藏
页码：S7 / S8
页数：2
相关论文
共 50 条
  • [21] Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey
    Das, Chandan
    Tripathy, Debasmita
    Swain, Surendranath
    Sudhakaran, Navin
    Uthansingh, Kanishka
    Mallick, Pradeep
    Pati, Girish K.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (05)
  • [22] Trends in pioglitazone use among US adults with type 2 diabetes and suspected nonalcoholic fatty liver disease
    Le, Phuc
    Chaitoff, Alexander
    Rothberg, Michael B.
    McCullough, Arthur
    Alkhouri, Naim
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (02) : 205 - 208
  • [23] Nonalcoholic fatty liver disease in type 2 diabetes mellitus
    Cusi, Kenneth
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2009, 16 (02) : 141 - 149
  • [24] Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease
    Raschi, Emanuel
    Mazzotti, Arianna
    Poluzzi, Elisabetta
    De Ponti, Fabrizio
    Marchesini, Giulio
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (17) : 1903 - 1914
  • [25] Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease and type 2 diabetes
    Pennisi, G.
    Enea, M.
    Falco, V.
    Aithal, G. P.
    Palaniyappan, N.
    Yilmaz, Y.
    Boursier, J.
    Cassinotto, C.
    De Ledinghen, V.
    Chan, W. K.
    Mahadeva, S.
    Eddowes, P.
    Newsome, P.
    Karlas, T.
    Wiegand, J.
    Wong, V. Wai-Sun
    Schattenberg, J. M.
    Labenz, C.
    Kim, W.
    Lee, M. S.
    Lupsor-Platon, M.
    Cobbold, J. F. L.
    Fan, J.
    Shen, F.
    Staufer, K.
    Trauner, M.
    Stauber, R.
    Nakajima, A.
    Yoneda, M.
    Bugianesi, E.
    Younes, R.
    Gaia, S.
    Zheng, M.
    Camma, C.
    Anstee, Q. M.
    Mozes, F. E.
    Pavlides, M.
    Petta, S.
    DIGESTIVE AND LIVER DISEASE, 2023, 55 : S12 - S13
  • [26] The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
    Dai, Chia-Yen
    Fang, Tzu-Jung
    Hung, Wei-Wen
    Tsai, Hui-Ju
    Tsai, Yi-Chun
    BIOMEDICINES, 2022, 10 (07)
  • [27] Efficacy and Safety of Sitagliptin Therapy Compared with Pioglitazone in Heart Failure Patients with Type 2 Diabetes
    Naka, Toshio
    Akagami, Takafumi
    Doi, Takashi
    Masuyama, Tohru
    Ohyanagi, Mitsumasa
    JOURNAL OF CARDIAC FAILURE, 2012, 18 (10) : S188 - S188
  • [28] The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes
    Younossi, Zobair M.
    Golabi, Pegah
    Price, Jillian Kallman
    Owrangi, Soroor
    Gundu-Rao, Nagashree
    Satchi, Romona
    Paik, James M.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (10) : 1999 - 2010
  • [29] Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes
    Gao, Xiuying
    Zhu, Chuanming
    Zhu, Wei
    Wang, Lin
    BIOMEDICAL REPORTS, 2025, 22 (02)
  • [30] IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE
    Bian, Hua
    Zhu, Xiaopeng
    Xia, Mingfeng
    Yan, Hongmei
    Chang, Xinxia
    Hu, Xiqi
    Pan, Baishen
    Guo, Wei
    Li, Xiaoying
    Gao, Xin
    ENDOCRINE PRACTICE, 2020, 26 (04) : 444 - 453
12345